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Background. Pathophysiological links between inﬂammation, obesity, and adipokines can be used for the treatment of metabolic
dysregulation. Aims. To examine the inﬂuence of duodenal-jejunal omega switch surgery in combination with diﬀerent diet
patterns on plasma concentrations of fatty acid-binding protein 4 (FABP4), C-reactive protein (CRP), leptin, and chemerin.
Methods. After 8 weeks on a high-fat diet (HF) or control diet (CD), rats underwent surgery. Duodenal-jejunal omega switch
(DJOS) with an exclusion of one-third of intestinal length and SHAM surgery were performed. For the next 8 weeks, 50% of
DJOS/SHAM animals were kept on the same diet as before (HF/DJOS/HF, HF/SHAM/HF, CD/DJOS/CD, and CD/SHAM/CD),
and 50% had a changed diet (HF/DJOS/CD, HF/SHAM/CD, CD/DJOS/HF, and CD/SHAM/HF). FABP4, CRP, leptin, and
chemerin were assessed using ELISA kits. Results. FABP4: signiﬁcant diﬀerences between DJOS and SHAM were observed in
animals maintained on CD/CD; CRP: varied between DJOS and SHAM groups maintained on HF/HF, CD/CD, and CD/HF;
leptin and chemerin levels: DJOS lowered leptin and chemerin plasma levels versus SHAM, while HF/HF, CD/HF, and HF/CD
signiﬁcantly increased leptin and chemerin plasma levels when compared to CD/CD. Conclusions. The beneﬁcial eﬀect of DJOS
surgery is stronger than proinﬂammatory conditions caused by an HF obesogenic diet.
1. Introduction
Systematic energy surplus with “unhealthy dietary patterns”
is known to be a strong driver in the development of obesity,
for which a chronic low-grade inﬂammatory condition called
metabolically triggered inﬂammation, metainﬂammation, or
parainﬂammation is characteristic [1, 2]. The condition of
chronic inﬂammation if occurs in metabolically involved
organs, like liver and adipose tissue, plays a main role in
the development of chronic metabolic diseases, such as
diabetes, and fatty liver disease [2]. Adipose tissue, aside from
controlling fat mass and nutrient homeostasis, realises an
inﬂammatory cytokine, which regulates metabolic homeosta-
sis and the immune response. Fatty acid-binding proteins
(FAPBs) are intracellular proteins known to facilitate lipid-
mediated processes in cells [3]. So far, 9 types of FAPBs have
been described and named in relation to the organ/tissue
expression [4]. FABP4, expressed by adipocytes and macro-
phages, plays a key role in regulating systemic metabolism.
It is an important mediator of inﬂammatory processes and
metabolic syndrome [1]. The low-grade systemic inﬂamma-
tion is as well characterised by C-reactive protein (CRP).
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CRP is produced in the liver on the binding of proinﬂamma-
tory cytokines and is associated with obesity [5]. Leptin is an
adipose-derived cytokine, which shows appetite-suppressant
acting mediated through hypothalamic signaling. Leptin-
resistant conditions, characteristic for obesity, lead to a loss
of hypothalamus control of appetite and feeding behavior,
exacerbating the already excessive body weight gain [6].
Leptin stimulates the gene expression of proinﬂammatory
cytokines such as tumor necrosis factor alpha (TNF-α),
interleukin 1 (IL-1), and interleukin (IL-6), improves phago-
cytosis by regulating oxidative stress, and acts on immune
cells [7–11]. Chemerin, also called retinoic acid receptor
responder 2 or tazarotene-induced gene 2, has been found
to be highly expressed in adipose tissue. Plasma total che-
merin concentrations are positively associated with obesity,
metabolic syndrome, and inﬂammation [12]. Chemerin
merges obesity with inﬂammation inactivating the orphan
G-protein coupled receptor chemokine-like receptor 1
(CMKLR1, ChemR23) which is characteristic for cells of
the innate immune system [12–15]. Bariatric surgery is one
of the most eﬃcient treatments for long-term weight loss
and its long-term maintenance [16]. A systematic review of
long-term follow-ups after bariatric surgery shows that this
is one of the most eﬃcient treatments of obesity, which helps
to reduce body weight by up to 60% during the ﬁrst two years
after surgery, and gives about a 38% reduction of comorbid-
ities in studied individuals [17]. Duodenal-jejunal omega
switch (DJOS) is a type of bariatric surgery, with proximal
loop duodeno-enterostomy, which bypasses the foregut
(foregut theory), and allows for direct hindgut stimulation
(hindgut theory) [18, 19]. The advantage of DJOS is a
bypass-like procedure, where the pylorus of the patients is
saved. This modiﬁcation prevents patients from symptoms
characteristic for postgastrectomy conditions such as dump-
ing, diarrhoea, and dyspepsia [20, 21]. DJOS is a relatively
new technique, thus an animal model, for exploring the
physiological long-term eﬀects of this procedure, is still
needed [20, 22].
A pathophysiological link between dietary patterns,
obesity, inﬂammation, and adipokines can be used as a
potential target in therapeutic strategies for treatment of
metabolic dysregulation like obesity, insulin resistance, and
T2DM. Thus, the aim of the study was to measure the impact
of DJOS surgery in combination with diﬀerent types of
dietary patterns on FABP4, leptin, chemerin, and CRP
plasma levels. In this study, we decided to use an HF diet in
order to induce obesity as a model close to human behaviour
for the investigation of the underlying mechanisms mediat-
ing metabolic beneﬁts of DJOS, measured by the plasma
levels of selected adipokines. The experimental design of this
study also includes the observations that not all patients after
surgery follow the nutritional recommendations [23, 24].
Many physiological and psychological factors inﬂuence post-
operative diﬀerences in weight-related outcomes, but it is
known that weight regain occurs in up to 20% of patients
after the surgery [25–27]. Thus, the selected study groups
diﬀer in terms of diet used before and after surgery. We
assumed that after a bariatric operation, one might switch
from a regular diet to an HF and from an HF to a regular
diet. Then, we assessed the eﬀect of duodenal-jejunal
omega switch surgery in combination with CD, and an
HF diet, before and after surgery, on the plasma levels of
selected adipokines.
2. Materials and Methods
2.1. Animals and Diets. This individual study is based on
experimental design applied and described in an earlier work
by Stygar et al. [28]. Seven-week-old, male Sprague–Dawley
rats (Charles River Laboratories Inc., Wilmington, MA) were
kept in 12 h light-dark cycles at 22°C and 40–60% humidity.
Environmental enrichment was provided, and all rats had
free access to water and food. The composition of control diet
(CD) was (Provimi Kliba AG, Kaiseraugst, Switzerland) 24%
protein, 4.9% fat, 7% crude ashes, 4.7% crude ﬁber, lysine
(13.6 g/kg), calcium (12 g/kg), methionine (4.5 g/kg), and
phosphorus (8.3 g/kg). The animals from the control group
were kept on CD for the period of two months, before
and after surgery. Obesity was induced by keeping the
animals on a high-fat diet (HF; 23.0 kJ/g; 59% fat, 27%
carbohydrate, and 14% protein (EF RAT [E15744] Ssniﬀ
Spezialdiäten GmbH, Soest, Germany)) for the period of
two months before and after surgery. All rats fasted over-
night before surgery.
3. Experimental Design
After one week of acclimatisation, the animals were assigned
to the experimental dietary patterns HF groups (n = 28) and
CD (n = 28). The total duration of the experiment was 16
weeks. The animals were kept on selected diets for the period
of 8 weeks before and 8 weeks after the DJOS and SHAM
surgery. The ﬁrst part of the protocol, before the surgery,
included 8 weeks of maintenance of animals on selected diets.
After this time, both groups (CD and HF) were divided into
two subgroups, which underwent diﬀerent types of surgery:
50% of rats underwent DJOS (14 animals) and 50% under-
went SHAM surgery, which is a control type of surgery
(14 animals, Figure 1(a)).
In the second part of the experiment, after the surgery,
50% of DJOS/SHAM animals were kept on the same diet
as before (HF/DJOS/HF, HF/SHAM/HF, CD/DJOS/CD,
and CD/SHAM/CD), and 50% had changed the diet (HF/
DJOS/CD, HF/SHAM/CD, CD/DJOS/HF, and CD/SHAM/
HF; Figure 1(a)). The “3Rs” for the ethical treatment of ani-
mals was followed in the study [29]. In the HF/SHAM/CD
subgroup, 6 out of 7 rats survived till the end of the experi-
ment, while in the rest of subgroups, the survival was 100%.
4. Experimental Procedures
A DJOS was performed according to Karcz et al. method-
ology [22], described in the aforementioned study [28].
To perform DJOS, the animals were anaesthetized with
2% isoﬂurane (AbbVie Deutschland GmbH & Co. KG,
Ludwigshafen, Germany) and oxygen ﬂow at 2 l/min under
spontaneous breathing. Analgesia with xylazine (5mg/kg,
ip; Xylapan, Vetoquinol Biovet, Poland) and antibiotic
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prophylaxis with gentamicin were applied. In order to gain
abdominal access, a midline incision of 3-4 cm was per-
formed, and the total length of the small intestine was deter-
mined (Figure 1(b)). The stomach was separated from the
duodenum at the point just below the pylorus, and the
position of anastomosis was deﬁned at 1/3 of the total small
bowel length. The jejunum was anastomosed via end-to-
side duodeno-enterostomy in order to restore the physiolog-
ical conduit of the food passage, excluding the duodenum
and parts of the small intestine. The remaining duodenal
stump was closed using PDS 6/0 (Ethicon). Mesenteric
openings were closed with PDS 6/0 (Ethicon).
In the SHAM-operated animals, reanastomosis of the
gastrointestinal tract was performed at the corresponding
sites where enterotomies were performed for the duodenoje-
junostomy, thereby maintaining continuity of the food
passage through the bowel (Figure 1(c)). For DJOS and
SHAM protocols, postoperative analgesia was performed
using carprofen (4mg/kg, sc; Rimadyl, Pﬁzer, Switzerland)
for 3 consecutive days after the surgery.
4.1. Tissue Collection and Assay Identiﬁcation. At the end of
the 8th week after surgery, corresponding to the 16th week
of the experiment, blood samples for adipokines and CRP
measurements were collected from the abdominal aorta,
using tubes containing 10μl EDTA (Sigma-Aldrich, St.
Louis, MO). After centrifugation at 4000 rpm for 10 minutes
at 4°C, plasma samples were collected, snap-frozen in liquid
Placebo surgeryDuodeno-jejunostomy Duodeno-jejunostomy Placebo surgery
High-fat diet
DJOS SHAM
Control diet
SHAMDJOS
High-fat dietHigh-fat diet High-fat diet High-fat diet
Control diet Control diet Control dietControl diet
(a)
⅓
Stomach
Duodenum-jejunum
Lleum
Caecum
Anus
Rectum
Jejunum
Anastomosis
(b)
Stomach
Duomedum
Lleum
Caecum
Anus
Rectum
Jejunum
Anastomosis
(c)
Figure 1: (a) Scheme of experimental groups. (b) Schematic illustration of DJOS. (c) SHAM surgery.
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nitrogen, and stored at −80°C until analyses were performed.
Adipokines, including FABP4, leptin, chemerin, and CRP,
were assessed in duplicate by using sandwich ELISA kits
(Cloud-Clone Corp., Katy, TX). All experimental proce-
dures were approved by the Ethical Committee for Animal
Experimentation (58/2014).
5. Statistical Analysis
Statistical analysis was performed using STATISTICA 12.5
PL (StatSoft, Cracow, Poland). Statistical signiﬁcance was
set at a p value below 0.05. All tests were two-tailed. Interval
data were expressed as mean value± standard deviation in
the case of normal distribution, or as median/lower–upper
quartile range in the case of data with skewed or nonnormal
distribution. Distribution of variables was evaluated by the
Shapiro-Wilk test and the quantile-quantile plot. The
homogeneity of variances was assessed by the Levene test.
For comparison of data, the two-way parametric ANOVA
and post hoc contrast analysis or nonparametric Kruskal-
Wallis test or Mann–Whitney U test were used. In case of
skewed data distribution, logarithmic transformation was
performed before analysis.
6. Results
The results of body weight change after DJOS and SHAM
surgery in all experimental groups were previously presented
by Stygar et al. [28]. Plasma concentrations of FABP4, CRP,
leptin, and chemerin in DJOS and SHAM-operated groups
after long-term maintenance on HF and CD and mixed
HF/CD and CD/HF eating patterns are shown in Table 1.
Table 2 presents results of multiple comparisons in
contrast analysis of DJOS and SHAM-operated groups in
relation to diet used before and after surgery. Column one
presents a comparison between DJOS and SHAM surgery
associated with diﬀerent diets, column two shows compari-
sons between dietary groups of DJOS operated animals, and
column three presents comparisons between dietary groups
of SHAM-operated animals.
6.1. Plasma Concentrations of FABP4. The type of diet
strongly inﬂuenced the FABP4 plasma levels both in animals
from the DJOS and SHAM groups. Signiﬁcant diﬀerences
between DJOS and SHAM groups were observed only in
animals maintained on CD diet before and after the surgery
(p < 0 01; Figure 2, Tables 1 and 2).
In animals after DJOS, approximately two times lower
plasma level of FABP4 was observed in the CD/CD group
compared with the HF/HF, HF/CD, and CD/HF groups
(p < 0 001; Figure 2, Tables 1 and 2).
In the control groups, plasma concentrations of FABP4
in rats subjected to HF diet before and after the surgery
(HF/HF) were signiﬁcantly higher than those in the groups
maintained on CD before the surgery (CD/HF p < 0 05 and
CD/CD p < 0 001; Figure 2, Tables 1 and 2). In addition,
the change from HF to CD diet signiﬁcantly increased
FABP4 level than the change from CD to HF and CD/CD
groups (p < 0 01 and p < 0 001, resp.; Figure 2, Tables 1
and 2).
6.2. Plasma Concentrations of CRP. The CRP concentrations
were consistently lower after DJOS compared with SHAM
surgery regardless of dietary pattern. CRP plasma concentra-
tions varied between DJOS and SHAM groups maintained
on HF diet before and after the surgery (p < 0 001), CD diet
(p < 0 05), and mixed CD/HF diet (p < 0 01; Figure 3,
Tables 1 and 2).
For both types of surgery, the values of CRP did not diﬀer
between selected experimental groups (Tables 1 and 2).
6.3. Plasma Concentrations of Leptin. DJOS surgery signiﬁ-
cantly lowered the leptin plasma level in comparison to
SHAM surgery despite the type of diet applied before and
after surgery (p < 0 001 for all; Figure 4, Tables 1 and 2).
HF diet signiﬁcantly increased leptin level when com-
pared to the CD/CD group in DJOS-operated animals (p <
0 001; Figure 4, Table 2). The maintenance of animals on
diﬀerent types of diet before and after surgery increased the
leptin plasma level but did not reduce the positive eﬀect of
DJOS. The CD/HF and HF/CD diets signiﬁcantly increased
leptin plasma levels when compared to the CD/CD group
(p < 0 001, resp.; Figure 4, Table 2).
Also in the SHAM-operated animals, the HF diet signiﬁ-
cantly increased the leptin level in comparison to the control
group (p < 0 001, resp.; Figure 4, Table 2).
6.4. Plasma Concentrations of Chemerin. DJOS surgery sig-
niﬁcantly lowered the chemerin plasma levels when com-
pared to SHAM surgery for all analysed groups, except CD/
HF (p < 0 001, 0.01, and 0.01, resp.; Figure 5, Tables 1 and 2).
After DJOS surgery, the highest level of chemerin was
observed in the HF/HF group in comparison with all other
analysed diet combinations, and it was signiﬁcantly higher
when compared to the CD/CD group (p < 0 001; Figure 5,
Table 2). The lowest level of chemerin was detected for the
CD/CD group, and this value was signiﬁcantly diﬀerent
from all other groups (p < 0 001, 0.01, and 0.001, resp.;
Figure 5, Table 2).
The type of food given to animals before and after SHAM
surgery inﬂuenced the chemerin plasma level in SHAM-
operated animals. The HF/HF diet changed the chemerin
plasma proﬁle in comparison with all other analysed groups
(p < 0 001, resp.; Figure 5, Table 2). Also, in group CD/CD,
the chemerin plasma level was signiﬁcantly lower when
compared to HF/CD groups (p < 0 01; Figure 5, Table 2).
7. Discussion
Patients with severe obesity need to adopt new dietary pat-
terns after metabolic surgery in order to achieve long-term
results. Our understanding of the eﬀect of bariatric surgery
on the systematic metabolism is still incomplete. It is not
possible to distinguish between the physiological eﬀects of
dietary changes, reduced food consumption, and the direct
eﬀects of metabolic surgery per se [30].
Our present study shows the inﬂuence of dietary patterns
applied before and after DJOS and SHAM surgery on the
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plasma FABP4 concentration. Despite the type of surgery, in
FABP4, the plasma levels were inﬂuenced by the type of
dietary pattern (HF and/or CD diet). HF led to the increase
in FABP4 plasma concentration, reducing the positive eﬀect
of DJOS. FABP4 is characteristic for adipose tissue and
macrophages, where it regulates adipocyte fatty-acid uptake
and lipogenesis, and also inﬂuences cholesterol accumula-
tion. It also delivers lipids to nuclear receptors, stimulating
nuclear transcriptional patterns. In macrophages, FABP4
is known to modulate inﬂammatory responses by the
connection to systemic inﬂammation and the immune
system [4, 31, 32]. The elevated plasma FABP4 level is
a negative prognostic factor, correlated with metabolic
syndrome, insulin resistance (calculated as HOMA-IR),
and mortality of patients with advanced hepatic cirrhosis
and sepsis [31, 33]. Witczak et al. observed signiﬁcant
changes in free plasma FABP4 concentrations with time,
after biliopancreatic diversion surgery. The highest level of
FABP4 was observed after the 1-month follow-up and might
be related to increased lipolysis after the surgery [34]. Some
studies show inconsistency regarding FABP4 plasma con-
centrations in patients after weight loss, which may be inter-
preted as a normalisation of FABP4 plasma level [34–36]. In
our previous study, we did not observe signiﬁcant weight
loss in rats maintained on an HF diet after DJOS surgery
[28]. As we demonstrate here, the HF diet before and/or
after both DJOS and control, SHAM surgery led to an
increase in FABP4 concentration in reference to the control
diet. We believe that an HF dietary pattern increases the
fatty acid metabolism and is connected with upregulated
FABP4 expression and secretion from the adipose tissue.
Obesity and an HF diet are associated with low-grade
chronic inﬂammation in many tissues, which is conﬁrmed
by increased plasma concentrations of CRP, tumor necrosis
factor α (TNF-α), and interleukins [5, 37]. Bariatric and
metabolic surgery shows a positive impact on the reduction
of inﬂammatory biomarkers in several tissues, for example,
adipose tissue [3]. CRP, primarily produced in the liver,
is known to be upregulated under conditions of obesity,
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Figure 2: Mean values of FABP4 (ng/ml) plasma levels in four groups subjected to diﬀerent dietary patterns, according to the DJOS and
SHAM operation type. Statistical signiﬁcance was set at p < 0 05. Vertical lines depict 95% conﬁdence interval. DJOS: duodenal-jejunal
omega switch surgery; HF: high-fat diet; CD: control diet; HF/HF, CD/HF, HF/CD, CD/CD: type of diet 8 weeks before/8 weeks after surgery.
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Figure 3: Mean values of CRP (ng/ml) plasma levels in four
groups of diﬀerent dietary patterns, according to the DJOS and
SHAM operation type. Statistical signiﬁcance was set at p < 0 05.
Vertical lines depict 95% conﬁdence interval. DJOS: duodenal-
jejunal omega switch surgery; HF: high-fat diet; CD: control diet;
HF/HF, CD/HF, HF/CD, CD/CD: type of diet 8 weeks before/
8 weeks after surgery.
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regardless of age, sex, or ethnicity of subjects studied [5].
As a marker of inﬂammation, plasma concentration of
CRP shows a strong and long-lasting decrease after bariatric
surgery [38–40]. In the present study, we combined meta-
bolic surgery with a regular and proinﬂammatory athero-
genic diet. After 16 weeks of experimental dietary patterns,
DJOS had a strong reductive inﬂuence on the CRP plasma
level, despite the type of diet used in the experiment, includ-
ing the HF/HF dietary pattern. A change of the diet from CD
to HF after surgery signiﬁcantly increased CRP plasma levels
in SHAM-operated animals when compared to DJOS. The
CRP concentrations were consistently lower in DJOS than
in SHAM-operated groups, which may be interpreted as a
modulation of inﬂammatory processes even in the conditions
of an atherogenic diet. The reduction of plasma CRP was
postulated to be associated with weight loss. In the human
studies, Selvin et al. observed that for every 1 kg loss of weight
in adults, the mean decrease in CRP plasma concentration
was 0.13mg/l, which is probably associated with reduced
hypertrophy of adipocytes and lipid storage in adipose tissue
[41, 42]. Although, we observed reduced CRP plasma levels
after DJOS surgery. Moreover, intragroup-related analyses
showed high variations in plasma CRP levels, which resulted
in the lack of signiﬁcant changes between the analysed
groups. We hypothesize that it can be explained by the
individual responses of the animals. Similar eﬀects were
observed in severely obese patients, where their gene poly-
morphisms were suggested to explain the interindividual
variability in circulating CRP [43]. We suggest that a decline
in CRP levels may be associated not only with body mass
reduction but also with metabolic changes in physiologic
proﬁles of subcutaneous adipose tissue and visceral adipose
tissue, lowered adipose inﬂammation, decreased proinﬂam-
matory adipokine production, and lower insulin resistance
induced by bariatric surgery [3].
The impaired cross-talk between the endocrine activity of
adipose tissue and other insulin-dependent organs is charac-
teristic for obesity and metabolic syndrome [44]. Leptin is the
main factor involved in the regulation of energy status,
stimulating satiety by metabolic communication between
adipose tissue and CNS. This proinﬂammatory adipokine
acts in the early phase of obesity-related inﬂammation, stim-
ulates proinﬂammatory immune responses, and plays an
important role in energy-deﬁcient states, such as fasting, diet,
or exercise-induced amenorrhea and lipoatrophy [3, 45]. To
the best of our knowledge, this is the ﬁrst study that presents
the eﬀects of DJOS surgery in combination with diﬀerent
dietary patterns on plasma leptin concentration. DJOS
showed a signiﬁcant impact on leptin plasma levels regard-
less of the diet applied before and after surgery. We observed
a strong eﬀect of DJOS on the leptin plasma levels in all
experimental groups when compared to SHAM groups.
The lowest level of leptin was observed in the CD/CD dietary
pattern in both DJOS and SHAM groups. The highest levels
of leptin were detected in conditions of proinﬂammatory
HF/HF dietary intervention before and after surgery. What
is interesting is that a change of the diet, in groups where
HF was combined with CD, also led to increased serum leptin
levels. As previously reported, bariatric surgery-induced
weight loss was associated with a positive eﬀect on the
endocrine activity of adipose tissue and plasma leptin levels,
which decreases independently of the type of surgery per-
formed: Roux-en-Y gastric bypass (RYGB) or laparoscopic
sleeve gastrectomy [46]. After RYGB, leptin (protein and
mRNA) decreased in patients with diabetes mellitus and
dyslipidemia [47]. As an appetite-related hormone, leptin
may play an important role in weight regain after obesity
therapy. Human studies show signiﬁcant reduction in leptin
blood concentrations in patients who lost at least 5% of body
mass using a hypocaloric diet (restriction of 30% of the
subject’s total energy expenditure) but also a more signiﬁcant
regain of body weight 6 months after the hypocaloric diet in
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Figure 4: Mean values of leptin (ng/ml) plasma levels in four groups
of diﬀerent dietary patterns, according to the DJOS and SHAM
operation type. Statistical signiﬁcance was set at p < 0 05. Vertical
lines depict 95% conﬁdence interval. DJOS: duodenal-jejunal
omega switch surgery; HF: high-fat diet; CD: control diet; HF/HF,
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Figure 5: Mean values of chemerin (ng/ml) plasma levels in four
groups of diﬀerent dietary patterns, according to the DJOS and
SHAM operation type. Statistical signiﬁcance was set at p < 0 05.
Vertical lines depict 95% conﬁdence interval. DJOS: duodenal-
jejunal omega switch surgery; HF: high-fat diet; CD: control diet;
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patients who have a higher baseline of fasting leptin levels
[48]. In the present study, we demonstrated that HF dietary
patterns introduced before or/and after surgery lead to
metabolic disturbances, reversing the eﬀects of DJOS and
increasing leptin plasma concentration in relation to the
control group.
In rodents, chemerin plasma levels were signiﬁcantly
increased in the conditions of dyslipidemia and diminished
after fasting [49]. In humans, elevated serum/plasma levels
of chemerin are correlated with body fat, glucose, lipid
metabolism, and inﬂammation which is connected with the
fact that this adipokine plays a role in the pathophysiology
of obesity and metabolic syndrome [50]. Animals fed HF diet
showed to be less responsive to chemerin and its physiologi-
cal actions, such as the regulation of adipogenesis in mature
adipocytes, through the activation of chemokine-like recep-
tor 1 (CMKLR1) [51]. Changes in plasma levels of chemerin
were reported after biliopancreatic diversion with duodenal
switch, which may be associated with improved insulin resis-
tance and resolution from hyperlipidemia [52]. Moreover,
changes in plasma chemerin levels have been reported to be
time-related and might be a consequence of an improved
metabolic phenotype and reduced serum insulin levels.
Studying the eﬀects of surgery in relation to eating patterns,
a similar trend in leptin and chemerin plasma levels was
observed, when comparing the DJOS and SHAM types of
surgery. Independently of dietary interventions, there were
signiﬁcantly lower chemerin plasma concentrations after
DJOS surgery than in SHAM-operated animals. In addition,
we demonstrated that the proinﬂammatory HF dietary pat-
tern used before or/and after surgery led to an increase in
chemerin plasma levels in comparison to CD/CD groups,
but did not reduce beneﬁcial eﬀects of DJOS.
8. Conclusions
It is concluded that DJOS surgery has a decreasing impact on
systemic levels of proinﬂammatory adipokines and CRP. The
beneﬁcial eﬀect of DJOS is strongly deteriorated by an HF
diet, in most of the studied combinations, before and/or after
surgery. Nevertheless, the beneﬁcial eﬀect of DJOS surgery is
stronger than proinﬂammatory conditions caused by an HF
obesogenic diet.
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